SRNE - Sorrento Therapeutics, Inc.
| Previous Close | 3.8400 |
| Open | 3.9100 |
| Bid | 3.4900 x 3100 |
| Ask | 3.5000 x 800 |
| Day's Range | 3.4500 - 3.9400 |
| 52 Week Range | 1.8000 - 8.4500 |
| Volume | 2,773,939 |
| Avg. Volume | 1,836,266 |
| Market Cap | 404.933M |
| Beta (3Y Monthly) | 2.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.17 |
- GlobeNewswire•9 days ago
Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
Yuhan) and Sorrento Therapeutics, Inc. (SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor. The mAb blocks the interaction of PD-L1 protein with its receptor PD-1, suppressing the inhibitory signal to T cells and enhancing the killing effect of T cells on tumors.
- GlobeNewswire•23 days ago
Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences
SAN DIEGO, Feb. 25, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that senior management will provide a corporate overview at the upcoming.
- GlobeNewswire•last month
Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program
The proceeds of the transaction will be utilized to advance ImmuneOncia’s Phase I and II clinical studies of IMC-001, a PD-L1 monoclonal antibody, as well as to support its earlier stage programs. As a result of this financing, ImmuneOncia is expected to be sufficiently funded in preparation for an initial public offering, which is expected to occur in 2021.
- Simply Wall St.•last month
What Kind Of Shareholders Own Sorrento Therapeutics, Inc. (NASDAQ:SRNE)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Sorrento Therapeutics,Read More...
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for Tapestry, FIS, News Corporation, Ollie's Bargain Outlet, Covanta Holding, and Sorrento Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Jan. 31, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE•2 months ago
Health Stocks Benefitting the Most from Rally
HENDERSON, NV / ACCESSWIRE / January 22, 2019 / The stock market reached a level toward the end of last year where investors and analysts feared a recession. Some of this fear was over a U.S. China trade ...
- GlobeNewswire•2 months ago
Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the phase 1b study of its non-opioid, afferent nerve ablating drug candidate (resiniferatoxin or “RTX”) for the treatment of pain from osteoarthritis in the knee (intra-articular route of administration) interim data analysis of over 30 patients had positive activity, prompting Sorrento to start planning pivotal studies to start in 2019. Rapid onset of pain relief (day following injection) and sustained clinical benefits (84 days) at the lowest dose tested. The “Phase 1b double-blind study to assess the safety and preliminary efficacy of intra-articular administration of resiniferatoxin versus placebo for the treatment of pain due to moderate to severe osteoarthritis of the knee” was expected to recruit about 40 patients in 5 dose level cohorts or until a maximum tolerated dose (MTD) was reached.
- GlobeNewswire•2 months ago
Scilex Announces Addition of ZTlido® to Express Scripts National Formularies
Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (SRNE), today announced that Express Scripts has added ZTlido® (lidocaine topical system) 1.8% to its commercial national formularies representing nearly 30 million lives. ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also referred to as post-shingles pain. “SCILEX worked diligently with Express Scripts to ensure that patients and providers will have access to ZTLIDO, a non-opioid, non-abusive treatment option for post-herpetic neuralgia,” said Mike Sweeting, Vice President, Market Access, Scilex. “Express Scripts’ decision to include ZTLIDO on its national formularies in recognition of the benefit it can provide to patients with post-herpetic neuralgia, or PHN, is an important milestone for SCILEX.
- GlobeNewswire•2 months ago
Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1)
Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (SRNE), today announced that ZTlido® (lidocaine topical system) 1.8% (ZTLIDO) is covered by nearly 100M U.S. insured lives1. ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also referred to as post-shingles pain. “SCILEX has been working closely with pharmacy benefit managers (PBMs) and health plans to help ensure patients and providers have access to ZTLIDO, a non-opioid, non-abusive treatment option for post-herpetic neuralgia,” said Mike Sweeting, Vice President, Market Access, Scilex. ZTLIDO is a topical system product that uses an advanced adhesion technology, providing more efficient lidocaine delivery than Lidoderm® (lidocaine patch 5%)* over a full 12 hours.
- GlobeNewswire•2 months ago
Dr. Henry Ji to Participate In Financing Expert Panel at East/West CEO Conference
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that Dr. Henry Ji, Chairman and CEO, will participate in the East/West CEO conference in San Francisco on January 5th, 2019 at 2:00PM PST at the Four Seasons Hotel San Francisco (prior to the JPM Healthcare Conference). The panel will discuss “Adventures in Financing: Raising Capital in 2018”, with a focus on alternative financing and how innovative biotechnology companies can leverage the value of their assets in commercial and/or development stage to seek significant non-dilutive funding.
- GlobeNewswire•4 months ago
Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million
Sorrento Therapeutics, Inc. (SRNE), a clinical-stage immunotherapy biotech company, announces the closing of a debt financing for up to $150 million. The financing is being provided by funds and accounts managed by Oaktree Capital Management, L.P. (“Oaktree”), a leading global investment firm.
- GlobeNewswire•4 months ago
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
Sorrento Therapeutics, Inc. (SRNE) ("Sorrento") announced today the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery (PEDD) manufactured by TriSalus™ Life Sciences. The preliminary data for the Hepatic Immunotherapy for Metastases (HITM-SURE) clinical trial results will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 7-11 in Washington, DC. Five patients, four pancreatic and one colorectal, with carcinoembryonic antigen–positive (CEA+), unresectable stage IV adenocarcinoma with liver metastases, who had failed one or more lines of systemic chemotherapy, each received three hepatic artery infusions of Sorrento autologous anti-CEA CAR-T cells using the Hepatic Immunotherapy for Metastases (HITM) method.
- GlobeNewswire•5 months ago
Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
Sorrento Therapeutics, Inc. (SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to evaluate the safety and efficacy of CD38 CAR-T therapy in relapsed or refractory multiple myeloma patients at two clinical sites – University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island. The CD38 CAR-T cells manufactured at both Sorrento cGMP facilities (San Diego, CA and Providence, RI) met all release specifications and were used in the study. This study is the first US-based clinical trial targeting CD38 using an autologous CAR-T cell therapy.
- Motley Fool•5 months ago
Here's Why Sorrento Therapeutics Fell 20.7% in September
A recently announced debt financing won't dilute shareholders, but it still has Wall Street worried.
- Kiplinger•5 months ago
10 Growth Stocks to Buy With Monster Potential
The stock market - especially growth stocks - is at an interesting inflection point as we enter the final quarter of 2018. On the one hand, the Standard & Poor's 500-stock index recovered from a tumultuous midyear with a 7% third-quarter gain that marked its best quarterly performance since 2013. On the other, interest-rate worries have sent a quick scare into the markets, and riskier, growth-oriented equities have suffered a bit of a pullback. Still, corporate earnings have impressed, unemployment remains at multi-decade lows and the economy is growing. So as we head into the seasonally strong fourth quarter, the question for anyone who still believes the broader trend is up becomes, "Which stocks are Wall Street analysts singling out as compelling investing opportunities?" We can use TipRanks to pinpoint top growth stocks - as identified by Wall Street's brightest minds - that have significant growth potential. Let's take a closer look at these 10 top picks now: SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)
- PR Newswire•6 months ago
Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation
- Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 - Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles ...
- Benzinga•7 months ago
Sorrento's Knee Pain Medication Found Safe, Effective Based On Early Data
Sorrento Therapeutics Inc (NASDAQ: SRNE ) shares were rallying Monday following the announcement of positive trial results for its osteoarthritis knee pain treatment candidate. In pre-market trading, the ...
